Verbal Memory Deficits Are Correlated with Prefrontal Hypometabolism in 18FDG PET of Recreational MDMA Users

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Bosch, Oliver G ^a   Wagner, Michael ^b,c   Jessen, Frank ^b,c   Kühn, Kai Uwe ^b,d   Joe, Alexius ^b   Seifritz, Erich ^a,e   Maier, Wolfgang ^b,c   Biersack, Hans Jürgen ^b   Quednow, Boris B ^a,b,e  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BIHEMISPHERIC LATERAL TEMPORAL CORTEX; BILATERAL DORSOLATERAL PREFRONTAL CORTEX; BILATERAL ORBITAL PREFRONTAL CORTEX; BILATERAL THALAMUS; BRAIN DYSFUNCTION; BRAIN GLUCOSE HYPOMETABOLISM; BRAIN METABOLISM; BRAIN REGION; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DECLARATIVE MEMORY; DRUG ABUSE; FUNCTIONAL NEUROIMAGING; HIPPOCAMPUS; HUMAN; INFERIOR PARIETAL CORTEX; LATERAL TEMPORAL CORTEX; LEARNING; LEARNING TEST; MALE; MEDIAL PREFRONTAL CORTEX; MEDIOTEMPORAL CORTEX; MEMORY DISORDER; MENTAL PERFORMANCE; NEUROPSYCHOLOGY; PATIENT ASSESSMENT; PONS; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; RAPHE NUCLEUS; RECALL; RECREATION; REY AUDITORY VERBAL LEARNING TEST; VERBAL DECLARATIVE MEMORY DEFICIT; VERBAL MEMORY; WORD RECOGNITION;

ADULT; BRAIN MAPPING; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MEMORY DISORDERS; MENTAL RECALL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PARIETAL LOBE; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; TEMPORAL LOBE; VERBAL LEARNING;

EID: 84876066981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061234     Document Type: Article

References (92)

1. Christophersen AS, (2000) Amphetamine designer drugs-an overview and epidemiology. Toxicol Lett 112-113: 127-131.
2. Sumnall HR, Cole JC, Jerome L, (2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 20: 670-682.
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2012) Annual report on the state of the drugs problem in Europe. Lisbon: European Monitoring Centre for Drugs and Drug Addiction.
4. United Nations Office on Drugs and Crime (UNODC) (2012) World Drug Report 2012. Vienna: United Nations.
5. Rudnick G, Wall SC, (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89: 1817-1821.
6. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55: 463-508.
7. Hagino Y, Takamatsu Y, Yamamoto H, Iwamura T, Murphy DL, et al. (2011) Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters. Curr Neuropharmacol 9: 91-95.
8. Anneken JH, Gudelsky GA, (2012) MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus. Neuropharmacology 63: 1022-1027.
9. Parrott AC, (2009) Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology 60: 148-158.
10. Lyles J, Cadet JL, (2003) Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms. Brain Res Brain Res Rev 42: 155-168.
11. Steinkellner T, Freissmuth M, Sitte HH, Montgomery T, (2011) The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. Biol Chem 392: 103-115.
12. Ali SF, Newport GD, Scallet AC, Binienda Z, Ferguson SA, et al. (1993) Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 15: 91-96.
13. Hatzidimitriou G, McCann UD, Ricaurte GA, (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107.
14. Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB, (1989) 3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J Pharmacol Exp Ther 249: 713-720.
15. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, et al. (1998) In vivo detection of short- and long-term MDMA neurotoxicity-a positron emission tomography study in the living baboon brain. Synapse 29: 183-192.
16. Wilson MA, Ricaurte GA, Molliver ME, (1989) Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28: 121-137.
17. McCann UD, Ridenour A, Shaham Y, Ricaurte GA, (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology 10: 129-138.
18. Ricaurte GA, Finnegan KT, Irwin I, Langston JW, (1990) Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations. Ann N Y Acad Sci 600: 699-708; discussion 708-610.
19. Bhattachary S, Powell JH, (2001) Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or 'ecstasy': evidence for cognitive impairment. Psychol Med 31: 647-658.
20. Fox HC, Toplis AS, Turner JJ, Parrott AC, (2001) Auditory verbal learning in drug-free Ecstasy polydrug users. Hum Psychopharmacol 16: 613-618.
21. Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J, (2003) Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog Neuropsychopharmacol Biol Psychiatry 27: 819-827.
22. Rodgers J, (2000) Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology (Berl) 151: 19-24.
23. Wareing M, Fisk JE, Murphy P, Montgomery C, (2004) Verbal working memory deficits in current and previous users of MDMA. Hum Psychopharmacol 19: 225-234.
24. Wareing M, Fisk JE, Murphy P, Montgomery C, (2005) Visuo-spatial working memory deficits in current and former users of MDMA ('ecstasy'). Hum Psychopharmacol 20: 115-123.
25. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA, (1999) Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl) 143: 417-425.
26. Morgan MJ, (1999) Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology (Berl) 141: 30-36.
27. Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, et al. (2006) Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 20: 373-384.
28. Bolla KI, McCann UD, Ricaurte GA, (1998) Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51: 1532-1537.
29. Croft RJ, Klugman A, Baldeweg T, Gruzelier JH, (2001) Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. Am J Psychiatry 158: 1687-1692.
30. Quednow BB, Kuhn KU, Hoenig K, Maier W, Wagner M, (2004) Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 29: 982-990.
31. Tuchtenhagen F, Daumann J, Norra C, Gobbele R, Becker S, et al. (2000) High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 22: 608-617.
32. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, et al. (1999) Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 175: 186-188.
33. Buchert R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, et al. (2001) Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl Med Commun 22: 889-897.
34. Obrocki J, Schmoldt A, Buchert R, Andresen B, Petersen K, et al. (2002) Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett 127: 285-297.
35. Moreno-Lopez L, Stamatakis EA, Fernandez-Serrano MJ, Gomez-Rio M, Rodriguez-Fernandez A, et al. (2012) Neural correlates of the severity of cocaine, heroin, alcohol, MDMA and cannabis use in polysubstance abusers: a resting-PET brain metabolism study. PLoS One 7: e39830.
36. Buchert R, Thiele F, Thomasius R, Wilke F, Petersen K, et al. (2007) Ecstasy-induced reduction of the availability of the brain serotonin transporter as revealed by [11C](+)McN5652-PET and the multi-linear reference tissue model: loss of transporters or artifact of tracer kinetic modelling? J Psychopharmacol 21: 628-634.
37. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, et al. (2003) Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 44: 375-384.
38. Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, et al. (2004) A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am J Psychiatry 161: 1181-1189.
39. Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, et al. (2010) Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 133: 1779-1797.
40. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA, (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352: 1433-1437.
41. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, et al. (2005) Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30: 1741-1750.
42. Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, et al. (2011) In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiatry 68: 562-576.
43. Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, et al. (2009) Brain serotonin transporter binding in former users of MDMA ('ecstasy'). Br J Psychiatry 194: 355-359.
44. Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, et al. (2002) The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 26: 387-396.
45. Di Iorio CR, Watkins TJ, Dietrich MS, Cao A, Blackford JU, et al. (2011) Evidence for Chronically Altered Serotonin Function in the Cerebral Cortex of Female 3,4-Methylenedioxymethamphetamine Polydrug Users. Arch Gen Psychiatry.
46. Urban NB, Girgis RR, Talbot PS, Kegeles LS, Xu X, et al. (2012) Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [(1)(1)C]DASB and [(1)(1)C]MDL 100907. Neuropsychopharmacology 37: 1465-1473.
47. Fox HC, McLean A, Turner JJ, Parrott AC, Rogers R, et al. (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology (Berl) 162: 203-214.
48. Becker B, Wagner D, Koester P, Bender K, Kabbasch C, et al. (2012) Memory-related hippocampal functioning in ecstasy and amphetamine users: A prospective fMRI study. Psychopharmacology (Berl).
49. Daumann J, Fischermann T, Heekeren K, Henke K, Thron A, et al. (2005) Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) 180: 607-611.
50. Daumann J Jr, Fischermann T, Heekeren K, Thron A, Gouzoulis-Mayfrank E, (2004) Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biol Psychiatry 56: 349-355.
51. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH, (2004) Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173: 383-390.
52. Moeller FG, Steinberg JL, Dougherty DM, Narayana PA, Kramer LA, et al. (2004) Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) 177: 185-194.
53. Daumann J, Fimm B, Willmes K, Thron A, Gouzoulis-Mayfrank E, (2003) Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Brain Res Cogn Brain Res 16: 479-487.
54. Roberts GM, Nestor L, Garavan H, (2009) Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task. Brain Res 1292: 71-81.
55. Quednow BB, Kuhn KU, Hoppe C, Westheide J, Maier W, et al. (2007) Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). Psychopharmacology (Berl) 189: 517-530.
56. Valdes IH, Steinberg JL, Narayana PA, Kramer LA, Dougherty DM, et al. (2006) Impulsivity and BOLD fMRI activation in MDMA users and healthy control subjects. Psychiatry Res 147: 239-242.
57. Kalechstein AD, De La Garza R, 2nd, Mahoney JJ, 3rd, Fantegrossi WE, Newton TF (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189: 531-537.
58. Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, et al. (2003) Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 6: 750-757.
59. de Win MM, Jager G, Booij J, Reneman L, Schilt T, et al. (2008) Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry 193: 289-296.
60. Hampel H, Teipel SJ, Alexander GE, Pogarell O, Rapoport SI, et al. (2002) In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. J Neural Transm 109: 837-855.
61. Kew JJ, Brooks DJ, Passingham RE, Rothwell JC, Frackowiak RS, et al. (1994) Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study. Neurology 44: 1101-1110.
62. Millien I, Blaizot X, Giffard C, Mezenge F, Insausti R, et al. (2002) Brain glucose hypometabolism after perirhinal lesions in baboons: implications for Alzheimer disease and aging. J Cereb Blood Flow Metab 22: 1248-1261.
63. Dzietko M, Sifringer M, Klaus J, Endesfelder S, Brait D, et al. (2010) Neurotoxic effects of MDMA (ecstasy) on the developing rodent brain. Dev Neurosci 32: 197-207.
64. Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, et al. (1988) (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. Jama 260: 51-55.
65. Rosenberg NL (1995) Basic principles of clinical neurotoxicology. In: Chang LW, Slikker W, Jr., editors. Neurotoxicology-Approaches and methods: Academic press.
66. Helmstaedter C, Lendt M, Lux S, (2001) Verbaler Lern- und Merkfähigkeitstest, Manual. Göttingen: Beltz.
67. Baddeley A, (2003) Working memory: looking back and looking forward. Nat Rev Neurosci 4: 829-839.
68. Alexander MP, Stuss DT, Fansabedian N, (2003) California Verbal Learning Test: performance by patients with focal frontal and non-frontal lesions. Brain 126: 1493-1503.
69. Ranganath C, Johnson MK, D'Esposito M, (2003) Prefrontal activity associated with working memory and episodic long-term memory. Neuropsychologia 41: 378-389.
70. Kuypers KP, Wingen M, Heinecke A, Formisano E, Ramaekers JG, (2011) MDMA intoxication and verbal memory performance: a placebo-controlled pharmaco-MRI study. J Psychopharmacol 25: 1053-1061.
71. Aggleton JP, Brown MW, (1999) Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci 22: 425-444; discussion 444-489.
72. Tulving E, Habib R, Nyberg L, Lepage M, McIntosh AR, (1999) Positron emission tomography correlations in and beyond medial temporal lobes. Hippocampus 9: 71-82.
73. Buckner RL, Andrews-Hanna JR, Schacter DL, (2008) The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124: 1-38.
74. Niendam TA, Laird AR, Ray KL, Dean YM, Glahn DC, et al. (2012) Meta-analytic evidence for a superordinate cognitive control network subserving diverse executive functions. Cogn Affect Behav Neurosci 12: 241-268.
75. Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G, (1995) Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci 15: 5476-5485.
76. Ricaurte GA, Martello AL, Katz JL, Martello MB, (1992) Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622.
77. Ensslin HK, Kovar KA, Maurer HH, (1996) Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J Chromatogr B Biomed Appl 683: 189-197.
78. Stuerenburg HJ, Petersen K, Baumer T, Rosenkranz M, Buhmann C, et al. (2002) Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuro Endocrinol Lett 23: 259-261.
79. Curran HV, (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34-41.
80. Newhouse PA, Potter AS, Dumas JA, Thiel CM, (2011) Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol 82: 943-951.
81. Wylie KP, Rojas DC, Tanabe J, Martin LF, Tregellas JR, (2012) Nicotine increases brain functional network efficiency. Neuroimage 63: 73-80.
82. Taffe MA, Davis SA, Yuan J, Schroeder R, Hatzidimitriou G, et al. (2002) Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology 27: 993-1005.
83. Hoyer D, Hannon JP, Martin GR, (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554.
84. Kish SJ, (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71: 845-855.
85. Quednow BB, Treyer V, Hasler F, Dorig N, Wyss MT, et al. (2012) Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage 59: 3922-3932.
86. Lehrl S, (2005) Mehrfachwahl-Wortschatz-Intelligenztest: MWT-B. Balingen.
87. Rey A (1964) L'examen de Clinique en Psychologie. Paris: Presses Universitaire de France.
88. Delis DC, Kramer J, Kaplan E, Ober BA (1987) California Verbal Learning Test, Adult Verision Manual. San Antonio, TX: Psychological Cooperation.
89. Forrester G, Geffen G, (1991) Performance measures of 7- to 15-year-old children on the Auditory Verbal Learning Test. The Clinical Neuropsychologist 5: 345-359.
90. Green DM, Swets JA (1966) Signal Detection Theory and Psychophysics. London: J. Wiley.
91. Bartenstein P, Asenbaum S, Catafau A, Halldin C, Pilowski L, et al. (2002) European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging 29: BP43-48.
92. Vul E, Pashler H, (2012) Voodoo and circularity errors. Neuroimage 62: 945-948.